Intercept Pharmaceuticals, Inc. (ICPT)

13.46 -0.23 (-1.68%) At close: 04:00PM EDT

Intercept Pharmaceuticals, Inc.

305 Madison Avenue
Morristown, NJ 07960
United States
646 747 1000
https://www.interceptpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 341

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jerome B. Durso	Pres, CEO & Director	1.16M	N/A	1968
Mr. Andrew Saik	Chief Financial Officer	485.07k	N/A	1969
Mr. Rocco Venezia	Chief Accounting Officer & Treasurer	660.62k	N/A	1976
Mr. Jared M. Freedberg J.D.	Gen. Counsel	691.46k	N/A	1968
Dr. M. Michelle Berrey M.D., M.P.H., MPH.	Pres of R&D and Chief Medical Officer	732.13k	N/A	1967
Mr. Nareg Sagherian	Exec. Director of Global Investor Relations	N/A	N/A	N/A
Mr. David Ford	Chief HR Officer	N/A	N/A	1970
Dr. Mark Pruzanski M.D.	Founder, Advisor & Director	N/A	N/A	1968
Ms. Linda M. Richardson	Exec. VP & Chief Commercial Officer	N/A	N/A	1964
Paul Nitschmann	Sr. VP of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.

Corporate governance

Intercept Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 March 2023 is 4. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 6; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.